ARGATROBAN PACKAGE INSERT PDF

Store in original package until time of use. Argatroban: Discard product if it contains particulate matter, is cloudy, or discolored – Do not freeze – Protect from . Baxter U.S. – Healthcare Professionals – ARGATROBAN Injection in % Sodium Chloride mg/ mL (1 mg/1 mL). Argatroban is approved by the US Food and Drug Administration .. 51 to minutes), package insert recommendations provide guidance on.

Author: Grojin Banos
Country: Estonia
Language: English (Spanish)
Genre: Photos
Published (Last): 19 February 2004
Pages: 361
PDF File Size: 8.20 Mb
ePub File Size: 12.35 Mb
ISBN: 591-9-18807-496-7
Downloads: 86022
Price: Free* [*Free Regsitration Required]
Uploader: Meztilkree

Antithrombotic Therapy and Prevention of Thrombosis. It is then eliminated in the feces through biliary excretion. Therefore it is suggested that when a VKA is introduced, argatroban and VKA pakage should be overlapped to avoid prothrombotic effects and to ensure continuous anticoagulation for the initial period of VKA treatment.

Moderate Due to the thrombocytopenic effects of nelarabine, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants. Patients receiving warfarin that initiate concomitant fish oil therapy should have their INR monitored more closely and the dose of warfarin adjusted accordingly.

Theoretically, the risk of bleeding may be increased, but some studies that combined these agents did not produce clinically significant bleeding events.

Lepirudin antibodies also display cross-sensitivity to bivalirudin. Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: The terminal elimination half-life is about 39 to 51 minutes.

Argatroban is highly selective for thrombin and has little or no effect on related serine proteases trypsin, factor Xa, plasmin, and kallikrein. All patients had serious underlying conditions and were receiving multiple concomitant medications.

Major An additive risk of bleeding may be seen in patients receiving thrombolytic agents with thrombin inhibitors. Inhibition of packags K synthesis due to alterations in the intestinal flora may be a mechanism; however, concurrent infection is also a potential risk factor for elevated INR.

Ginger inhibits thromboxane synthetase platelet aggregation inducer and is a prostacyclin agonist. Ginkgo, Ginkgo biloba is reported to inhibit platelet aggregation and several case reports describe bleeding complications with Ginkgo biloba, with or without concomitant drug therapy.

Caution argatrobwn be exercised when administering Exembol Multidose to patients with hepatic disease, by starting with a lower dose and carefully titrating until the desired level of anticoagulation is achieved see section 4.

  DOLE OSH STANDARDS PDF

[Full text] Update on argatroban for the prophylaxis and treatment of heparin-indu | JBM

Sulfinpyrazone is a platelet inhibitor and exhibits antithrombotic actions in addition to its uricosuric effects. Based on population pharmacokinetic modelling, clearance in paediatric patients 0. The safe and effective dose or the effective target range for aPTT or activated clotting time ACT of Exembol Multidose argatrobxn not insegt clearly established in this patient population Currently available data are described in Section 5.

Major Because hemin has exhibited transient, mild anticoagulant effects during clinical studies, concurrent use of anticoagulants should be avoided. In patients undergoing PCI, these were chest pain, hypotension, back pain, nausea, vomiting, and headache.

It is also used as an adjunct therapy for percutaneous coronary intervention PCI in patients who have or are at risk of thrombosis due to HIT. If life-threatening bleeding occurs and excessive plasma levels of argatroban are suspected, Exembol Multidose should be discontinued immediately and aPTT and other coagulation tests should be performed.

Major An additive risk of bleeding may be seen in patients inesrt bivalirudin with argatroban.

Exembol Multidose 100 mg/ml concentrate for solution for infusion

Warkentin TE, Greinacher A. In addition, high fluid intake may increase lithium excretion. When heparins promote thrombosis: Argatroban has a relatively short elimination half-life of approximately 45 minutes, which is predominantly performed via hepatic metabolism.

Argatroban is highly selective for thrombin; inhibitory constant Ki values in studies in vitro with synthetic tripeptides ranged from 5 to 39 nM. As the authors suggest, argatroban should be initiated at a dose of 0.

An arfatroban range target for the INR in this situation is not given, but at very high INR levels the patient may be over-anticoagulated. Received 11 February Moderate Increased effects from concomitant anticoagulant drugs such as packahe bruising or blood in the stool have been reported in patients taking methylsulfonylmethane, MSM. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.

Absorption Steady-state levels of both argatroban and anticoagulant effect are typically attained within hours and are maintained until the infusion is discontinued or the dosage adjusted. For the primary end point, there was no statistically significant difference observed among DTIs. Aminosalicylate sodium, Aminosalicylic acid: As only limited data apckage available, an initial continuous infusion rate of 0.

  DRDOS ATTACK PDF

The ratio of diastereoisomers is unchanged by metabolism or hepatic impairment, remaining constant at Argatroban in the management of heparin-induced thrombocytopenia. In case of an elevated aPTT greater than 3 times baseline or secondsthe infusion should be discontinued until the aPTT is within the desired range of 1. Prasterone is also contraindicated in patients with active arterial thromboembolic disease for example, stroke and myocardial infarctionargatrobwn a history of these conditions.

Qualitative and quantitative composition 3. One vial with 2. Major and Minor hemorrhagic reactions have been observed in clinical trials. Moderate An additive risk of qrgatroban may be seen in thrombocytopenic patients receiving antineoplastic agents and anticoagulants concomitantly.

PDR Search

If used concurrently, monitor patients closely for bleeding at the IM injection site. Severe bleeding events have occurred with ibrutinib therapy including intracranial hemorrhage, GI bleeding, hematuria, and post procedural hemorrhage; some events argatroba fatal. The patient should be closely monitored with frequent evaluation of the INR and clinical parameter, and the dosage of warfarin should pakcage adjusted as necessary until a stable target INR is achieved.

ACT should be checked 5 to arfatroban minutes after the bolus dose is completed. INR should be measured daily while Exembol Multidose and oral anticoagulants are co-administered. In clinical trials, there have been 14 reports of intracranial bleeding intracranial hemorrhage, ICHincluding 8 fatalities, in 13 out of 6, HIV infected patients receiving tipranavir as part of combination antiretroviral therapy. The metabolites identified M-1, M-2, and M-3 are formed by hydroxylation and aromatization of the 3-methyltetrahydroquinoline packwge in the liver.

Since ginkgo produces clinically-significant antiplatelet effects, it should be used cautiously in patients drugs that inhibit platelet aggregation or pose a risk for bleeding, such as anticoagulants e. Other in-use storage times and conditions are the responsibility of the user.

VPN